Investigating ADR mechanisms with Explainable AI: a feasibility study with knowledge graph mining.
Adverse drug reaction
Data mining
Explainable AI
Explanation
Knowledge graph
Machine learning
Mechanism of action
Molecular mechanism
Journal
BMC medical informatics and decision making
ISSN: 1472-6947
Titre abrégé: BMC Med Inform Decis Mak
Pays: England
ID NLM: 101088682
Informations de publication
Date de publication:
26 05 2021
26 05 2021
Historique:
received:
15
12
2020
accepted:
05
05
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
11
6
2021
Statut:
epublish
Résumé
Adverse drug reactions (ADRs) are statistically characterized within randomized clinical trials and postmarketing pharmacovigilance, but their molecular mechanism remains unknown in most cases. This is true even for hepatic or skin toxicities, which are classically monitored during drug design. Aside from clinical trials, many elements of knowledge about drug ingredients are available in open-access knowledge graphs, such as their properties, interactions, or involvements in pathways. In addition, drug classifications that label drugs as either causative or not for several ADRs, have been established. We propose in this paper to mine knowledge graphs for identifying biomolecular features that may enable automatically reproducing expert classifications that distinguish drugs causative or not for a given type of ADR. In an Explainable AI perspective, we explore simple classification techniques such as Decision Trees and Classification Rules because they provide human-readable models, which explain the classification itself, but may also provide elements of explanation for molecular mechanisms behind ADRs. In summary, (1) we mine a knowledge graph for features; (2) we train classifiers at distinguishing, on the basis of extracted features, drugs associated or not with two commonly monitored ADRs: drug-induced liver injuries (DILI) and severe cutaneous adverse reactions (SCAR); (3) we isolate features that are both efficient in reproducing expert classifications and interpretable by experts (i.e., Gene Ontology terms, drug targets, or pathway names); and (4) we manually evaluate in a mini-study how they may be explanatory. Extracted features reproduce with a good fidelity classifications of drugs causative or not for DILI and SCAR (Accuracy = 0.74 and 0.81, respectively). Experts fully agreed that 73% and 38% of the most discriminative features are possibly explanatory for DILI and SCAR, respectively; and partially agreed (2/3) for 90% and 77% of them. Knowledge graphs provide sufficiently diverse features to enable simple and explainable models to distinguish between drugs that are causative or not for ADRs. In addition to explaining classifications, most discriminative features appear to be good candidates for investigating ADR mechanisms further.
Sections du résumé
BACKGROUND
Adverse drug reactions (ADRs) are statistically characterized within randomized clinical trials and postmarketing pharmacovigilance, but their molecular mechanism remains unknown in most cases. This is true even for hepatic or skin toxicities, which are classically monitored during drug design. Aside from clinical trials, many elements of knowledge about drug ingredients are available in open-access knowledge graphs, such as their properties, interactions, or involvements in pathways. In addition, drug classifications that label drugs as either causative or not for several ADRs, have been established.
METHODS
We propose in this paper to mine knowledge graphs for identifying biomolecular features that may enable automatically reproducing expert classifications that distinguish drugs causative or not for a given type of ADR. In an Explainable AI perspective, we explore simple classification techniques such as Decision Trees and Classification Rules because they provide human-readable models, which explain the classification itself, but may also provide elements of explanation for molecular mechanisms behind ADRs. In summary, (1) we mine a knowledge graph for features; (2) we train classifiers at distinguishing, on the basis of extracted features, drugs associated or not with two commonly monitored ADRs: drug-induced liver injuries (DILI) and severe cutaneous adverse reactions (SCAR); (3) we isolate features that are both efficient in reproducing expert classifications and interpretable by experts (i.e., Gene Ontology terms, drug targets, or pathway names); and (4) we manually evaluate in a mini-study how they may be explanatory.
RESULTS
Extracted features reproduce with a good fidelity classifications of drugs causative or not for DILI and SCAR (Accuracy = 0.74 and 0.81, respectively). Experts fully agreed that 73% and 38% of the most discriminative features are possibly explanatory for DILI and SCAR, respectively; and partially agreed (2/3) for 90% and 77% of them.
CONCLUSION
Knowledge graphs provide sufficiently diverse features to enable simple and explainable models to distinguish between drugs that are causative or not for ADRs. In addition to explaining classifications, most discriminative features appear to be good candidates for investigating ADR mechanisms further.
Identifiants
pubmed: 34039343
doi: 10.1186/s12911-021-01518-6
pii: 10.1186/s12911-021-01518-6
pmc: PMC8157660
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-15-CE23-0028
Organisme : Agence Nationale de la Recherche
ID : 15-RHUS-0004
Références
Clin Pharmacol Ther. 2010 Jul;88(1):60-8
pubmed: 20375998
Curr Pharm Des. 2016;22(23):3498-526
pubmed: 27157416
BMC Bioinformatics. 2010 May 17;11:255
pubmed: 20478034
Curr Opin Drug Discov Devel. 2010 Jan;13(1):78-85
pubmed: 20047148
Sci Rep. 2016 Nov 02;6:36325
pubmed: 27805066
Eur J Clin Pharmacol. 2013 Nov;69(11):1909-16
pubmed: 23774940
Wiley Interdiscip Rev Syst Biol Med. 2016 Mar-Apr;8(2):104-22
pubmed: 26559926
Brief Bioinform. 2019 Jan 18;20(1):190-202
pubmed: 28968655
Am J Gastroenterol. 2014 May;109(5):620-3
pubmed: 24796999
Am J Physiol. 1998 Nov;275(5):G874-8
pubmed: 9815013
Proc Int World Wide Web Conf. 2017 Apr;2017:321-329
pubmed: 29479581
Sci Rep. 2017 Nov 27;7(1):16416
pubmed: 29180758
Nat Med. 2010 Apr;16(4):347
pubmed: 20376007
Adv Neural Inf Process Syst. 2019 Dec;32:9240-9251
pubmed: 32265580
PLoS One. 2010 Aug 23;5(8):e12063
pubmed: 20808786
BMC Bioinformatics. 2013 Jun 26;14:207
pubmed: 23802887
BMC Bioinformatics. 2011 Mar 29;12 Suppl 2:S2
pubmed: 21489221
Drug Discov Today. 2016 Apr;21(4):648-53
pubmed: 26948801
Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84
pubmed: 19757412
BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):139
pubmed: 30999867
NPJ Digit Med. 2019 Sep 10;2:90
pubmed: 31531395
Mitochondrion. 2016 Nov;31:63-74
pubmed: 27771494
J Biomed Semantics. 2017 Apr 20;8(1):16
pubmed: 28427468